Tiny study hopes antiviral drug eases dangerous liver pressure
NCT ID NCT04863703
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure in the liver's blood vessels. They will measure pressure changes and quality of life over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bulevirtide
- What this could lead to
- If successful, this study could show that viral suppression with Bulevirtide lowers portal hypertension, potentially improving outcomes for patients with hepatitis delta and cirrhosis.
- What could go wrong
- This is a very small observational study (11 participants) with no control group, so results may not be generalizable. It only measures changes in pressure, not long-term clinical benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hannover Medical School
Hanover, Lower Saxony, 30625, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- A new procedure may offer relief for Cirrhosis-Related fluid buildup
- Can extra doses of an old drug reverse liver scarring?
- Can liver damage predict how drugs behave?
- Better crystal ball for liver crisis: new scores put to the test
- Blood thinner may stop early cirrhosis from turning deadly — a major trial puts it to the test